Dyadic International (DYAI) Net Cash Flow Growth (3y) (2021 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn | -10.13% |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn | -98.96% |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | -8.34% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 36.60% |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn | -35.85% |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn | 67.39% |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn | -96.44% |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - | -47.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -47.38% |
| Dec 31, 2025 | -12.18% |
| Sep 30, 2025 | 46.85% |
| Jun 30, 2025 | 28.06% |
| Mar 31, 2025 | 24.31% |
| Dec 31, 2024 | -34.56% |
| Sep 30, 2024 | 13.50% |
| Jun 30, 2024 | -26.00% |
| Mar 31, 2024 | 26.00% |
| Dec 31, 2023 | 10.11% |
| Sep 30, 2023 | -46.23% |
| Jun 30, 2023 | -27.56% |
| Mar 31, 2023 | 88.43% |
| Dec 31, 2022 | -97.82% |
| Sep 30, 2022 | -202.02% |
| Jun 30, 2022 | -77.49% |
| Mar 31, 2022 | -59.86% |
| Dec 31, 2021 | 45.80% |
| Sep 30, 2021 | 39.60% |
| Jun 30, 2021 | 1,652.35% |